Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keynote-122: Pembrolizumab in NPC
NCT02611960Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2016
- Primary completion
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Merck & Co. Primary endpoint: Overall Survival at 53 months. Started Apr 2016; status: completed.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02611960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02611960.